QIAGEN announced the launch of its QuantiFERON-EBV RUO (research use only) assay. The company notes that QuantiFERON-EBV RUO was designed to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies by utilizing highly specific EBV antigens to stimulate a cell-mediated immune response, offering a view of the host’s active immune engagement with the virus. QuantiFERON-EBV RUO uses a combination of CD4+ and CD8+ antigens specific to EBV nuclear antigen proteins to stimulate lymphocytes in heparinized whole blood.
